Business News

Tamil Nadu court recalls NBW against DMK leader Ponmudi in hate speech case

FinSiddhi

A city magistrate recalled a non-bailable warrant against DMK leader K Ponmudi. He appeared before the court and sought the recall of the warrant. The hate speech case involves alleged derogatory remarks made by the former minister. The court ordered the recall and adjourned the case for further hearing. The warrant was issued earlier due to his absence from proceedings.
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.

Related Posts

In 1971, a Kenyan cement company tested 26 tree species in a barren limestone quarry; only three survived and became the foundation of a 200-hectare restoration project

A Kenyan limestone quarry, once barren, became a vibrant ecosystem over fifty years. Pioneer trees like Casuarina equisetifolia initiated soil restoration and provided essential shade. Millipedes played a crucial role in breaking down tough leaf litter into fertile humus. This ecological succession allowed diverse plant and animal species to naturally colonize the area. The Bamburi…

Blocked artery, failed liver cancer treatment: How doctors used a rare three-hour procedure to reach the tumour and deliver targeted Y-90 therapy

In a remarkable medical endeavor, a Yemeni man suffering from advanced liver cancer underwent a sophisticated treatment in India. Following unsuccessful prior therapies, doctors performed transarterial radioembolization, skillfully maneuvering through blocked arteries using collateral vessels. The treatment’s success was marked by the delivery of radioactive beads to the liver tumor, resulting in improved follow-up evaluations…

Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth

Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.